Plexiform neurofibroma genesis: Questions of Nf1 gene dose and hyperactive mast cells

Current Opinion in Hematology

Volumn 17, Issue 4, 2010, Pages 287-293

  Staser, Karl ^a,b   Yang, Feng Chun ^a,b   Clapp, David W ^a,b  

^a Department of Biochemistry ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c kit; mast cells; neurofibroma; neurofibromatosis type 1; tumor microenvironment

Indexed keywords

IMATINIB; NEUROFIBROMIN;

BONE MARROW; CLINICAL TRIAL; DRUG MECHANISM; GENE DOSAGE; HETEROZYGOSITY; HUMAN; MAST CELL; MICROENVIRONMENT; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; PATHOGENESIS; PLEXIFORM NEUROFIBROMA; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; TUMOR SUPPRESSOR GENE; ANIMAL; BIOLOGICAL MODEL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAST CELLS; MICE; MODELS, GENETIC; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMIN 1; SCHWANN CELLS;

EID: 77954072798     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328339511b     Document Type: Review

References (69)

1. von Recklinghausen F. Uber die Multiplen Fibrome der Haut und ihre Bezie-hung zu Multiplen Neuromen. Berlin, Germany: August Hirschwald; 1882.
2. Friedman J, Gutmann DH, Maccollin M, Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. 3rd ed. Baltimore, Maryland, USA: The Johns Hopkins University Press; 1999.
3. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 1993; 10:335-343.
4. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med 2010; 12:1-11.
5. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123:124-133.
6. Greggio H. Les cellules granuleuses (Mastzellen) dans les tissus normaux et dans certaines maladies chirurgicales. Arch Med Exp 1911; 23:323-375.
7. Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neuro-surg Focus 28:E8.
8. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002; 296:920-922.
9. Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene 2007; 26:4609-4616.
10. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a micro-environment containing Nf1 +/~ and c-kit-dependent bone marrow. Cell 2008; 135:437-448.
11. Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astro cyte and glioma growth. Hum Mol Genet 2007; 16:1098-1112.
12. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell 2009; 4:453-463.
13. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13:105-116.
14. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12:137-143.
15. Powers JF, Evinger MJ, Zhi J, et al. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience 2007; 147:928-937.
16. De Schepper S, Maertens O, Callens T, et al. Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol 2008; 128:1050-1053.
17. CuiY, Costa RM, Murphy GG, etal. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008; 135:549-560.
18. Li H, Liu Y, Zhang Q, etal. Ras dependent paracrine secretion of osteopontin by Nf1+/-osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr Res 2009; 65:613-618.
19. Lasater EA, Bessler WK, Mead LE, et al. Nf1+/~ mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum Mol Genet 2008; 17:2336-2344.
20. Yeh TH, Lee da Y, Gianino SM, Gutmann DH. Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 2009; 57:1239-1249.
21. Ingram DA, Yang FC, Travers JB, etal. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 2000; 191:181-188.
22. Diwakar G, Zhang D, Jiang S, Hornyak TJ. Neurofibromin as a regulator of melanocyte development and differentiation. J Cell Sci 2008; 121:167-177.
23. Bajenaru ML, Donahoe J, Corral T, etal. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 2001; 33:314-323.
24. Yan J, Chen S, Zhang Y, etal. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet 2008; 17:936-948.
25. Yang FC, Chen S, Robling AG, et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsuffi-cient osteoclast functions. J Clin Invest 2006; 116:2880-2891.
26. Munchhof AM, Li F, White HA, etal. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum Mol Genet 2006; 15:1858-1869.
27. Li F, Munchhof AM, White HA, etal. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum Mol Genet 2006; 15:1921-1930.
28. Atit RP, Mitchell K, Nguyen L, etal. The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J Invest Dermatol 2000; 114:1093-1100.
29. Yang FC, Chen S, Clegg T, et al. Nf1 +/~ mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet 2006; 15:2421-2437.
30. Jacks T, Shih TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7:353-361.
31. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994; 8:1019-1029.
32. Cichowski K, Shih TS, Schmitt E, etal. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286:2172-2176. (Pubitemid 129516295)
33. Zhu Y, Romero MI, Ghosh P, et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001; 15:859-876.
34. Hirota S, Nomura S, Asada H, etal. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med 1993; 117:996-999.
35. Ryan JJ, Klein KA, Neuberger TJ, et al. Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 1994; 37:415-432.
36. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol 1993; 142:965-974.
37. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
38. Gounaris E, Erdman SE, Restaino C, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 2007; 104:19977-19982.
39. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-631.
40. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008; 49:7-19.
41. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008; 8:478-486.
42. Nocka K, Tan JC, Chiu E, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 1990; 9:1805-1813.
43. Joseph NM, Mosher JT, Buchstaller J, et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008; 13:129-140.
44. Zheng H, Chang L, Patel N, et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell 2008; 13:117-128.
45. Yang FC, Ingram DA, Chen S, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1 +/~ mast cells. J Clin Invest 2003; 112:1851-1861.
46. Jaakkola S, Peltonen J, Riccardi V, etal. Type 1 neurofibromatosis: selective expression of extracellular matrix genes by Schwann cells, perineurial cells, and fibroblasts in mixed cultures. J Clin Invest 1989; 84:253-261.
47. Monk KR, Wu J, Williams JP, et al. Mast cells can contribute to axon-glial dissociation and fibrosis in peripheral nerve. Neuron Glia Biol 2007; 3:233-244.
48. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991; 349:117-127.
49. Hall A. Signal transduction through small GTPases: a tale of two GAPs. Cell 1992; 69:389-391.
50. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62:599-608.
51. Ballester R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990; 63:851-859.
52. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249:181-186.
53. Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63:843-849.
54. Khalaf WF, Yang FC, Chen S, et al. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/~ mast cells. J Immunol 2007; 178:2527-2534.
55. McDaniel AS, Allen JD, Park SJ, et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/~ mast cells. Blood 2008; 112:4646-4654.
56. Ingram DA, Hiatt K, King AJ, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001; 194:57-69.
57. Yang FC, Kapur R, King AJ, et al. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 2000; 12:557-568.
58. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-3310.
59. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 2007; 26:3227-3239.
60. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112:4808-4817.
61. Zhang Y, Taylor BR, Shannon K, Clapp DW. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest 2001; 108:709-715.
62. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med 1998; 187:1893-1902.
63. Bollag G, Clapp DW, Shih S, etal. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996; 12:144-148.
64. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997; 336:1713-1720.
65. Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003; 63:8573-8577.
66. Sabbagh A, Pasmant E, Laurendeau I, et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 2009; 18:2768-2778.
67. Gregorian C, Nakashima J, Dry SM, et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA 2009; 106:19479-19484.
68. Miller SJ, Jessen WJ, Mehta T, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009; 1:236-248.
69. McGillicuddy LT, Fromm JA, Hollstein PE, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009; 16:44-54.